中文摘要：

在这个工作，修改酸的 chitosan (mGA-suc-CTS ) 用作肝的 glycyrrhetinic 为药交货指向了搬运人，作为一个衔接的组经由 hemisuccinate 被准备。产品的结构被红外和 NMR 方法和 glycyrrhetinic 酸组的替换(DS ) 的度证实经由元素的分析被估计。Nanoparticles 被离子的冻结形成遇见的抓住。装载药并且 nanoparticles 的版本行为作为模型药用 BSA 被调查。结果显示有 5.19% 的最高的 DS 的搬运人能被得到， DS 被改变反应温度控制或喂比率。BSA 能与 26.3% 的装载药的比率和 81.5% 的封装效率被骗诱进 nanoparticles。在一个 11 天的时期上的一个持续版本在 pH 被观察 7.4 在 vitro。

英文摘要：

In this work, glycyrrhetinic acid-modified chitosan （mGA-suc-CTS） used as liver targeted carrier for drug delivery, was prepared via hemisuccinate as a bridged group. The structure of the product was confirmed by IR and NMR methods and the degree of substitution （DS） of glycyrrhetinic acid groups was estimated via elemental analysis. Nanoparticles were formed by ionic gelation methold. The drug-loading and release behavior of the nanoparticles were investigated using BSA as the model drug. The results indicated that the carrier with a highest DS of 5.19% could be got and the DS was controlled by changing reaction temperature or feed ratio. BSA could be entrapped into the nanoparticles with the drug-loading ratio of 26.3% and the encapsulation efficiency of 81.5%. A sustained release over an 11-day period was observed in pH 7.4 in vitro.